Vir Biotechnology, Inc. $VIR Holdings Lowered by Citigroup Inc.

Citigroup Inc. reduced its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 22.2% in the third quarter, HoldingsChannel reports. The fund owned 323,525 shares of the company’s stock after selling 92,426 shares during the quarter. Citigroup Inc.’s holdings in Vir Biotechnology were worth $1,847,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in VIR. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology during the second quarter valued at approximately $65,100,000. Aberdeen Group plc lifted its position in Vir Biotechnology by 51.6% in the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after purchasing an additional 519,374 shares during the period. Ensign Peak Advisors Inc lifted its position in Vir Biotechnology by 812.7% in the second quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock worth $2,938,000 after purchasing an additional 519,107 shares during the period. Woodline Partners LP boosted its stake in Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its stake in Vir Biotechnology by 100.7% during the 2nd quarter. Corient Private Wealth LLC now owns 518,684 shares of the company’s stock valued at $2,614,000 after purchasing an additional 260,308 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Insider Activity

In other Vir Biotechnology news, EVP Verneuil Vanina De sold 13,700 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total transaction of $134,534.00. Following the sale, the executive vice president owned 112,982 shares in the company, valued at approximately $1,109,483.24. The trade was a 10.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $9.51, for a total value of $209,220.00. Following the sale, the director owned 1,122,391 shares in the company, valued at approximately $10,673,938.41. The trade was a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 177,546 shares of company stock valued at $1,522,174 over the last three months. Insiders own 16.00% of the company’s stock.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: HC Wainwright materially raised its FY2026 outlook (now -$0.81 vs prior -$2.16) and flipped Q2 2026 to a $0.73 EPS forecast, signaling expectations for much stronger near‑term results; the firm retained a “Buy” rating and $20 price target.
• Positive Sentiment: HC Wainwright also nudged several 2026 quarterly estimates higher (Q3/Q4 2026 less negative), which supports the narrative of improving near‑term fundamentals and likely helped lift sentiment.
• Positive Sentiment: Management change: Vir named CEO Marianne De Backer as President, expanding her responsibilities — a governance move that can be read as streamlining decision‑making and execution. Vir Biotechnology Names CEO Marianne De Backer as President
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $20 target — a supportive endorsement but already priced in by some investors given previous coverage.
• Negative Sentiment: HC Wainwright trimmed longer‑term forecasts: FY2027 was lowered (to -$1.99 from -$1.90) and FY2028/FY2029 estimates were reduced (e.g., FY2028 to -$1.65 from -$1.40; FY2029 to -$1.24 from -$1.13), reflecting weaker medium‑term profitability expectations that could cap upside if sustained.

Vir Biotechnology Stock Performance

NASDAQ VIR opened at $9.55 on Monday. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94. The business’s fifty day moving average is $7.34 and its two-hundred day moving average is $6.27. The stock has a market capitalization of $1.33 billion, a P/E ratio of -3.02 and a beta of 1.65.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The company’s revenue was up 417.8% compared to the same quarter last year. During the same period last year, the company posted ($0.76) EPS. On average, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on VIR. Barclays boosted their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. Morgan Stanley raised their target price on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. Raymond James Financial raised Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 target price on the stock in a report on Tuesday, February 24th. Leerink Partners reiterated an “outperform” rating and issued a $20.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 26th. Finally, HC Wainwright upped their price target on shares of Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.44.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.